Ad
related to: potency pharmacology of amoxicillin 2 times 6 equal tablets mg capsules
Search results
Results From The WOW.Com Content Network
In pharmacology, potency or biological potency [1] is a measure of a drug's biological activity expressed in terms of the dose required to produce a pharmacological effect of given intensity. [2]
The minimum inhibitory concentration (MIC) and minimum bactericidal concentration are used to measure in vitro activity of antimicrobial agents. They are good indicators of antimicrobial potency, but don't give any information relating to time-dependent antimicrobial killing (the so-called post antibiotic effect).
For example, two products may both be amoxicillin, but one may come in 500 mg capsules, while another may be in 250 mg chewable tablets. The term unit dose can also refer to non-reusable packaging, particularly when each drug product is individually packaged. [1]
Amoxicillin is in the β-lactam family of antibiotics. [9] Amoxicillin was discovered in 1958 and came into medical use in 1972. [12] [13] Amoxil was approved for medical use in the United States in 1974, [4] [5] and in the United Kingdom in 1977. [2] It is on the World Health Organization's List of Essential Medicines. [14]
Acute use (1–3 days) yields a potency about 1.5× stronger than that of morphine and chronic use (7 days+) yields a potency about 2.5 to 5× that of morphine. Similarly, the effect of tramadol increases after consecutive dosing due to the accumulation of its active metabolite and an increase of the oral bioavailability in chronic use.
The AUC (from zero to infinity) represents the total drug exposure across time. AUC is a useful metric when trying to determine whether two formulations of the same dose (for example a capsule and a tablet) result in equal amounts of tissue or plasma exposure.
Other natural products, this time primary metabolites rather than secondary metabolites, have been shown to eradicate antibiotic tolerance. For example, glucose , mannitol , and fructose reduce antibiotic tolerance in Escherichia coli and Staphylococcus aureus , rendering them more susceptible to killing by aminoglycoside antibiotics.
[2] [3] However, when a medication is administered via routes other than intravenous, its bioavailability is lower due to intestinal epithelium absorption and first-pass metabolism. Thereby, mathematically, bioavailability equals the ratio of comparing the area under the plasma drug concentration curve versus time (AUC) for the extravascular ...